Premium
Prostatic effects induced in dogs by chronic or acute oral administration of 5α‐reductase inhibitors
Author(s) -
Brooks J. R.,
Berman C.,
Garnes D.,
Giltinan D.,
Malatesta P. F.,
Primka R. L.,
Reynolds G. F.,
Rasmusson G. H.,
Gordon L. R.
Publication year - 1986
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990090110
Subject(s) - prostate , medicine , oral administration , dihydrotestosterone , testosterone (patch) , histology , reductase , endocrinology , finasteride , androgen , enzyme , hormone , chemistry , cancer , biochemistry
A series of 4‐azasteroidal 5α‐reductase inhibitors was tested in dogs to determine the effect of 1) chronic (35–44 day) oral administration on prostate size and histology and 2) acute oral administration on prostatic concentrations of testosterone (T) and dihydrotestosterone (DHT). The extent to which the results of the two tests were correlated was also studied in order to see whether the acute test could be used to predict activity in the chronic test. Six Δ 1 analogs of the potent 5α‐reductase inhibitor, 4‐MA (17 β‐N,N‐diethylcarbamoyl‐4‐aza‐4‐methyl‐5α‐androstan‐3‐one) were uniformly active at low dosage levels (⩽ 3 mg/kg) in both types of assay whereas several C 1 ‐C 2 saturated analogs exhibited little activity in the chronic test. The nature of the side chain and whether there was a methyl or a proton at 4‐N did not dramatically influence the activity of Δ 1 compounds. There was a broad general agreement between the results of the two kinds of test in that if a compound acutely decreased the prostatic concentration of DHT it was likely to reduce prostate size and alter prostatic histology when given on a chronic basis.